ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Endo International plc

Minerva House
First Floor Simmonscourt Road Ballsbridge
Dublin 4
Ireland
353 1 268 2000
http://www.endo.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees2,910

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul V. CampanelliPres, CEO & Director2.82MN/A1962
Mr. Blaise ColemanExec. VP & CFO1.33MN/A1974
Mr. Terrance J. CoughlinExec. VP & COO1.41MN/A1966
Mr. Matthew Joseph MalettaExec. VP & Chief Legal Officer1.17MN/A1972
Mr. Antonio R. PeraPres of Par Pharmaceutical909.47kN/A1957
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provides branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain, and orthopedics. This segment offers XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL Nasal Spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN Gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; FORTESTA Gel for men suffering from hypogonadism; EDEX to treat erectile dysfunction; and TESTIM for TRT in conditions associated with a deficiency or absence of endogenous testosterone. The company's U.S. Branded - Sterile Injectables segment offers branded sterile injectable products, such as VASOSTRICT, ADRENALIN, and APLISOL; and generic sterile injectable products. Its U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. The company was founded in 1920 and is headquartered in Dublin, Ireland.

Corporate Governance

Endo International plc’s ISS Governance QualityScore as of April 1, 2019 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.